Analytical Data
-
Gene name
FGFR-3 alpha (IIIb)
- Application
-
Alternative Names
ACH; CD333; CEK; CEK2; EC 2.7.10; FGF R3; FGFR3; HSFGFR3EX; JTK4
-
Species
Mouse
-
Source
HEK293
-
Tag
C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
E9QNJ9
-
Expression Region
P22-V349
-
Protein Length
Partial
-
Molecular Weight
53-70 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibroblast Growth Factor Receptor 3 (FGFR3) is a key player in various cellular processes, including growth, differentiation, and tissue repair. It is part of the FGFR family, which consists of four members, and is primarily associated with skeletal development and homeostasis. FGFR3 harbors specific isoforms, with the alpha (IIIb) form being particularly significant due to its expression patterns in different tissues. Mutations in the FGFR3 gene are linked to a range of skeletal disorders, including achondroplasia and thanatophoric dysplasia. These mutations often lead to aberrant signaling pathways, resulting in impaired bone growth and development. Research into FGFR3 alpha (IIIb) recombinant proteins has garnered attention for the potential development of targeted therapies to mitigate the effects of these mutations. By producing and studying the recombinant form of FGFR3 alpha (IIIb), scientists aim to better understand its functional roles and the molecular mechanisms underlying related pathologies. Furthermore, investigating the protein's interactions and downstream signaling pathways could pave the way for novel therapeutic approaches, such as small molecules or monoclonal antibodies, aiming to correct or compensate for the dysregulated signaling caused by FGFR3 mutations. Overall, the study of FGFR3 alpha (IIIb) recombinant protein holds promise for advancing knowledge in developmental biology and for developing clinical strategies to treat FGFR-related disorders.
